Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)
Sponsor: Abbott Medical Devices
This NA trial investigates Atherosclerosis and Carotid Artery Disease and is currently terminated or withdrawn. Abbott Medical Devices leads this study, which shows 11 recorded versions since 2005 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated NA
-
Dec 2018 — Jan 2021 [monthly]
Terminated NA
-
Jun 2018 — Dec 2018 [monthly]
Terminated NA
-
Aug 2017 — Jun 2018 [monthly]
Terminated NA
Phase: PHASE3 → NA
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Atlanta, United States, Austin, United States, Baltimore, United States, Beaver, United States, Boston, United States, Buffalo, United States, Camden, United States, Chicago, United States, Cleveland, United States and 45 more location s